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The immune status of women changes during and after pregnancy, differs between 38 
blood compartments at delivery and is affected by environmental factors particularly in 39 
tropical areas endemic for multiple infections. We quantified the plasma concentration 40 
of a set of thirty-one TH1, TH2, TH17 and regulatory cytokines, pro-inflammatory and 41 
anti-inflammatory cytokines and chemokines, and growth factors (altogether 42 
biomarkers), in a cohort of 540 pregnant women from five malaria-endemic tropical 43 
countries. Samples were collected at recruitment (first antenatal visit), delivery 44 
(periphery, cord and placenta) and postpartum, allowing a longitudinal analysis. We 45 
found the lowest concentration of biomarkers at recruitment and the highest at 46 
postpartum, with few exceptions. Among them, IL-6, HGF and TGF-β had the highest 47 
levels at delivery, and even higher concentrations in the placenta compared to 48 
peripheral blood. Placental concentrations were generally higher than peripheral, 49 
except for eotaxin that was lower. We also compared plasma biomarker concentration 50 
between the tropical cohort and a control group from Spain at delivery, presenting 51 
overall higher biomarker levels the tropical cohort, particularly pro-inflammatory 52 
cytokines and growth factors. Only IL-6 presented lower levels in the tropical group. 53 
Moreover, a principal component analysis of biomarker concentrations at delivery 54 
showed that women from Spain grouped more homogenously, and that IL-6 and IL-8 55 
clustered together in the tropical cohort but not in the Spanish one. Plasma cytokine 56 
concentrations correlated with Plasmodium antibody levels at postpartum but not 57 
during pregnancy. This basal profiling of immune mediators over gestation and in 58 
different compartments at delivery is important to subsequently understand response 59 
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1. Introduction 65 
The immune system adapts during pregnancy to tolerate the semiallogenic fetus while 66 
protecting both the mother and fetus from infections. From a clinical point of view, this 67 
immune alteration manifests as worsening or mitigation of certain autoimmune 68 
diseases during gestation (1,2) and increased incidence and/or severity of some 69 
infectious diseases (reviewed in 3). The T helper (TH)2/TH1 cytokine paradigm, 70 
according to which successful pregnancies depend on a switch to a TH2 response, was 71 
accepted for a long time (4). However, controlled pro-inflammatory cytokine responses 72 
during gestation are necessary during embryo implantation, placentation, labor and 73 
defense against infections (5). As the status of the immune system evolves during 74 
pregnancy, some studies have investigated longitudinal changes in cytokines over 75 
different trimesters or compared to postpartum (6–8), showing in general a decrease 76 
in levels over pregnancy with some exceptions and conflicting results. Other studies 77 
focused on the distinct patterns present in the peripheral, placental and cord 78 
compartments at delivery (9,10). 79 
Although chemokines and growth factors are essential mediators in the development 80 
and communication of immune cells, they have been less well studied in pregnancy. 81 
With few exceptions (6,8), prior works have only analyzed limited sets of biomarkers, 82 
while a wider breath of responses needs to be simultaneously studied to unravel the 83 
complex relationships between cytokine networks.  84 
Immunity is influenced by hereditability and the environment (11), including exposure 85 
to infectious diseases. We have previously described how both pregnancy and malaria 86 
can have distinct effects on B and T cells, as well as Plasmodium-specific cytokine 87 
responses in endemic populations, and how these alterations may impact pregnancy 88 
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outcomes (12–14). Moreover, recurrent infections by Plasmodium falciparum and/or 89 
P. vivax in malaria-endemic areas cause chronic activation and alteration of the 90 
immune system (13,15–17). 91 
As part of a series of studies profiling humoral and cellular immune responses in 92 
pregnancy in a diverse cohort of pregnant women from five countries where malaria 93 
and other infectious diseases are endemic, we set out to assess plasma biomarkers in 94 
peripheral, cord and placental blood samples collected during pregnancy, at delivery 95 
and after the puerperium. The heterogeneity of the cohort in relation to malaria 96 
endemicity was addressed with available antibody data reflecting exposure to P. 97 
falciparum and P. vivax antigens. We selected a comprehensive set of TH1, TH2, TH17 98 
and regulatory cytokines, pro-inflammatory and anti-inflammatory cytokines and 99 
chemokines, and growth factors, to cover the main immune functions attributed to 100 
these biomarkers, towards understanding the basal conditions of these women 101 
cohorts, during and after pregnancy. This information is essential to subsequently 102 
analyze the effect of infections with significant impact on pregnancy such as malaria, 103 





2. Materials and methods 107 
2.1. Study design and population  108 
This study was performed in the context of a health facility-based observational study 109 
of pregnant women aimed to determine the burden of P. vivax infection in pregnancy, 110 
conducted between 2008 and 2012 in five countries of different P. vivax and P. 111 
falciparum endemicity: Brazil (BR), Colombia (CO), Guatemala (GT), India (IN) and 112 
Papua New Guinea (PNG). Approximately 2,000 women per site were recruited at the 113 
first antenatal visit (which in some cases occurred late in pregnancy, including the third 114 
trimester), and followed up until delivery. A random subgroup of 10% constituted the 115 
immunology cohort that was invited to return to the clinic at postpartum (at least 10 116 
weeks after delivery). A venous blood sample was collected at recruitment, delivery 117 
and postpartum for immunological assessment. Samples collected at recruitment and 118 
postpartum were obtained in the morning, as visits were scheduled at that time. 119 
Plasmas obtained at delivery were sampled just after the baby was born.  120 
In addition, total cord blood was collected at delivery and placental blood was obtained 121 
in CO and PNG from small incisions on the maternal facing sides. P. vivax and P. 122 
falciparum parasitemia were assessed in blood smears. 123 
For this particular study, 50 recruitment samples per country were randomly selected 124 
and analyzed with their paired delivery and postpartum samples. When paired 125 
recruitment/delivery/postpartum samples available were less than 50, additional 126 
random samples were included to achieve N=50. Because postpartum follow-up was 127 
low in some countries, it was not always possible to achieve N=50. In addition, total 128 
samples available in IN were fewer than 50 for the three time points, as plasma vials 129 
had been freeze-thawed several times which is known to be deleterious for cytokine 130 
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concentration. Therefore only samples with a second untouched vial available were 131 
measured. A total of 61 paired periphery-cord plasmas and 101 paired periphery-132 
placenta plasmas were analyzed. For the delivery analysis, peripheral plasma samples 133 
from pregnant women who were unexposed to malaria recruited in Barcelona-Spain 134 
(BCN) were also included (n=16) (naïve control group). 135 
 The protocol was approved by the national and/or local ethics committees of 136 
each recruiting site, the CDC IRB (USA), and the Hospital Clinic Ethics Review 137 
Committee (Barcelona, Spain, registry 2007/3978). Written informed consent was 138 
obtained from all study participants. 139 
2.2. Isolation of plasma 140 
Five to 10 mL of venous, cord and placental blood were collected aseptically in 141 
heparinized tubes. Plasma was separated from the cellular fraction by centrifugation 142 
at 600 x g for 10 min at room temperature (RT), aliquoted and stored at -80ºC. To 143 
minimize inter-site variability, samples from BR, CO, GT and PNG were shipped to the 144 
Barcelona Institute for Global Health in dry ice for measurement of cytokines, 145 
chemokines and growth factors (henceforth referred to as biomarkers). Samples from 146 
IN were analyzed at ICGEB, Delhi (India). 147 
2.3. Multiplex bead array assay  148 
Plasmas were thawed at 4ºC overnight and biomarkers analyzed with a multiplex 149 
suspension detection system, the Cytokine Magnetic 30-Plex Panel (Invitrogen, 150 
Madrid, Spain) that allows detection of the following biomarkers: epidermal growth 151 
factor (EGF), Eotaxin-1/CCL11, fibroblast growth factor (FGF), granulocyte colony-152 
stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-153 
CSF), hepatocyte growth factor (HGF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, 154 
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IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-10, IL-12(p40/p70), IL-13, IL-155 
15, IL-17, IFN-γ induced protein (IP-10/CXCL10), monocyte chemoattractant protein 156 
(MCP-1/CCL2), monokine induced by IFN-γ (MIG/CXCL9), macrophage inflammatory 157 
protein (MIP)-1α/CCL3, MIP-1β/CCL4, regulated on activation, normal T cell 158 
expressed and secreted (RANTES/CCL5), tumor necrosis factor (TNF), and vascular 159 
endothelial growth factor (VEGF). Fifty μL of the plasma samples were tested in single 160 
replicates (dilution 1:2, recommended by the vendor) in 96-well flat-bottom plates. 161 
Each plate contained serial dilutions (1:3) in duplicates of a standard sample of known 162 
concentration of each analyte provided by the manufacturer, as well as two blank 163 
controls and a control in duplicate of medium concentration prepared from a reference 164 
sample for quality control purposes. Upper and lower values of the standard curves for 165 
each analyte are displayed in Supplementary table 1.  166 
The assays were carried out according to the manufacturer’s instructions. Beads were 167 
acquired on the BioPlex100 system (Bio-Rad, Hercules, CA) and concentrations 168 
calculated using the Bioplex software. When values were out of range (OOR) 169 
according to the software, the following were assigned: for OOR values under the 170 
curves, a value three-times lower than the lowest standard concentration was assigned 171 
(as standard dilutions were 1:3), and for OOR values above the curve, a value three-172 
times higher than the highest standard concentration was assigned. Moreover, the 173 
software extrapolated values below and above the lower and higher concentrations, 174 
respectively, of the standard curves when they fitted into the curves and were not OOR. 175 
These values were kept as they were extrapolated by the software, with the exception 176 
of values below three-times the lowest standard concentration and above three-times 177 
the highest standard concentration, for which those respective values were assigned.  178 
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In addition, the cytokine transforming growth factor (TGF)-b1 was analyzed in all 179 
plasmas except those from IN, with a DuoSet ELISA kit (R&D Systems). Following the 180 
vendor’s recommendations, latent TGF-b1 was activated to its immunoreactive form 181 
with HCl and neutralized with NaOH/HEPES. A 40-fold plasma dilution was used. 182 
2.4. Quantification of IgG antibodies 183 
Measurement of plasma IgG antibodies at each time point was performed by an in-184 
house multiplex suspension array assay using the Luminex™ technology. Antigens 185 
used corresponded to different P. falciparum and P. vivax stages (sporozoite, 186 
merozoite and proteins expressed on the erythrocyte surface) and included: PfMSP-187 
119 (18), PfAMA-1 (19), PfEBA175 (PfF2) (20), DBL3X, DBL5ε, DBL6ε (21), Pv200L 188 
(PvMSP1121–416) (22), PvMSP-119 (23), PvCSP-N, PvCSP-C, PvCSP-R (24), full-length 189 
PvCSP, full-length PvMSP-5 (25), PvDBP (RII) (26), PvLP1, PvLP 2 (27), and VIR 190 
proteins (14). Magnetics beads (xMAP technology) were covalently coupled with the 191 
antigens. Beads were mixed in a single batch and ∼1000 beads per analyte were 192 
incubated with each plasma sample (dilution 1:100) in duplicates, and subsequently 193 
with anti-human IgG-biotin (Sigma-Aldrich), followed by streptavidin-conjugated R-PE 194 
(Fluka, Madrid, Spain). Beads were analyzed on the BioPlex100 system (Bio-Rad, 195 
Hercules, CA), and results were expressed as median fluorescence intensity.  196 
2.5. Statistical methods 197 
To compare biomarker concentrations between recruitment, delivery and postpartum, 198 
a two-way crossed-effects model was estimated, with the subject effect being crossed 199 
with the site effects. For this objective, pairwise statistical significance was interpreted 200 
based on 95% confidence intervals, considering significant when the interval did not 201 
include 0. To compare the biomarker concentrations between paired periphery and 202 
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placental plasma samples or paired periphery and cord plasma samples, a Wilcoxon 203 
matched-pairs signed rank test was performed. P-values were corrected for multiple 204 
comparisons with the Benjamini-Hochberg test. To compare biomarker concentrations 205 
among sites at delivery, a Kruskal-Wallis test was performed followed by Dunn's 206 
multiple comparisons test of BCN vs. each other country. Additionally, a principal 207 
component analysis (PCA) was performed to asses how a) cytokines and b) study 208 
subjects analyzed at delivery clustered, excluding TGF-β as this cytokine was analyzed 209 
by a differetn technique (ELISA) and was not measured in IN. To analyze the 210 
association between biomarker concentrations and anti-malarial antibody levels, the 211 
Spearman’s correlation test was used and the result classified based on the rho 212 
coefficient as: very weak (0-|0.19|), weak (|0.2|-|0.39|), moderate (|0.4|-|0.59|), strong 213 
(|0.6|-|0.79|) and very strong (|0.8|-|1|). Only results with p-value <0.05 (after 214 
adjustment for multiple comparisons, Benjamini-Hochberg test) and rho value >0.4 215 
were considered ‘biologically relevant’.  216 
Overall, significance was defined at p<0.05. Analyses and graphs were performed 217 
using Stata/SE 10.1 (College Station, TX, USA) and GraphPad Prism (La Jolla, CA, 218 
USA). 219 
 220 
3. Results 221 
3.1. Study population 222 
A total of 797 plasma samples collected in 546 women from the five tropical countries 223 
at different compartments and timepoints were analyzed. The number of samples 224 
included in the analysis by site and time point are provided in Supplementary table 2. 225 
Addititonally, 16 peripheral plasma samples collected from women in BCN were 226 
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analyzed. Characteristics of the cohort are shown in Supplementary table 3. 227 
Prevalence of P. vivax and P. falciparum infection at recruitment was 1.7% and 2.5%, 228 
respectively and at delivery 0.97% and 0.48% respectively (data not shown).  229 
3.2. Effect of pregnancy and labor on plasma biomarker concentrations 230 
To assess any specific effect of pregnancy and/or labor on blood biomarkers, we 231 
compared concentrations measured in plasma at recruitment, delivery and postpartum 232 
in the tropical cohort. Overall, recruitment samples presented the lowest concentration 233 
and postpartum samples the highest, with the exception of IL-1β, IL-6, TGF-β, IL-2, 234 
























Table 1. Pregnancy and labor effect on biomarker concentration. 257 
 258 
Two-way crossed-effect model, with the subject effect being crossed with the site effect. Only samples 259 
from the tropical countries were analized in the model, N=618. CI: confidence interval. Expected change: 260 
change in mean concentration measured in pg/mL. 261 
 262 




change 95% CI 
Expected 
change 95% CI 
Pro-inflammatory 
TNF 0 0.15 0.01; 0.29 0.27 0.11; 0.43 0.0026 
IL-1β 0 0.31 0.17; 0.45 0.25 0.10; 0.41 < 0.0001 
IL-6 0 1.47 1.26; 1.68 0.62 0.40; 0.85 < 0.0001 
Anti-inflammatory 
IL-10 0 -0.02 -0.14; 0.11 0.02 -0.12; 0.16 0.8900 
TGF-β 0 0.38 0.28; 0.48 0.22 0.11; 0.32 < 0.0001 
IL-1RA 0 0.38 0.21; 0.54 0.61 0.43; 0.79 < 0.0001 
IFN-α 0 0.11 0.01; 0.21 0.27 0.16; 0.37 < 0.0001 
Chemokines 
IL-8 0 1.13 0.78; 1.48 1.29 0.92; 1.67 < 0.0001 
MIP-1α 0 0.22 0.07; 0.37 0.5 0.33; 0.66 < 0.0001 
MIP-1β 0 0.37 0.16; 0.58 0.86 0.62; 1.09 < 0.0001 
MCP1 0 0.34 0.19; 0.48 0.93 0.77; 1.08 < 0.0001 
IP10 0 0.1 -0.00; 0.20 0.07 -0.04; 0.18 0.1398 
EOTAXIN 0 0.14 0.03; 0.25 0.91 0.79; 1.02 < 0.0001 
RANTES 0 0.13 0.02; 0.23 0.11 -0.00; 0.23 0.0455 
MIG 0 -0.09 -0.25; 0.08 0.58 0.40; 0.76 < 0.0001 
TH1 
IFN-γ 0 0.01 -0.06; 0.08 0.18 0.11; 0.26 < 0.0001 
IL-12 0 0.01 -0.06; 0.08 0.29 0.22; 0.37 < 0.0001 
IL-2 0 0.4 0.23; 0.56 0.25 0.07; 0.44 < 0.0001 
IL-15 0 0.35 0.21; 0.49 0.35 0.20; 0.51 < 0.0001 
IL-2R 0 0.04 -0.07; 0.15 0.31 0.18; 0.43 < 0.0001 
TH2 
IL-4 0 0.06 0.00; 0.12 0.11 0.04; 0.18 0.0039 
IL-5 0 0.09 -0.04; 0.22 0.3 0.15; 0.44 0.0002 
IL-13 0 0.2 0.07; 0.33 0.52 0.38; 0.67 < 0.0001 
TH17 IL-17 0 0.05 -0.04; 0.14 0.25 0.15; 0.35 < 0.0001 
Growth factors 
EGF 0 0.2 0.06; 0.34 0.56 0.40; 0.71 < 0.0001 
FGF 0 0.51 0.32; 0.69 0.45 0.24; 0.65 < 0.0001 
HGF 0 0.8 0.60; 1.00 0.16 -0.06; 0.38 < 0.0001 
VEGF 0 0.4 0.28; 0.52 0.68 0.55; 0.81 < 0.0001 
G-CSF 0 -0.01 -0.08; 0.07 0.16 0.08; 0.24 < 0.0001 
GM-CSF 0 0.03 -0.14; 0.20 0.15 -0.03; 0.34 0.2496 
IL-7 0 0.29 0.12; 0.47 0.7 0.51; 0.89 < 0.0001 
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As concentrations at delivery were significantly higher than at recruitment for many 263 
biomarkers, we wondered whether there was a gradual increase throughout pregnancy 264 
or rather a labor-specific up-regulation or release of biomarkers. At recruitment, the 265 
correlation between the biomarker concentrations and women’s gestational age 266 
(women were enrolled throughout the whole pregnancy) was low in all cases 267 
(Spearman’s rho<|0.33| in all cases, Supplementary table 4).  268 
3.3. Comparison of biomarker concentrations in placental, cord and peripheral 269 
blood at delivery 270 
Next, we assessed whether biomarker concentrations differed between blood 271 
compartments at delivery in the tropical cohort. We evaluated separately periphery vs. 272 
placenta and periphery vs. cord blood due to the low number of paired samples.  273 
For the biomarkers with significant differences between placenta and periphery, 274 
concentrations were always higher in placental than peripheral blood: pro-inflammatory 275 
biomarkers IL-6, IL-8, MIP-1α, MIP-1β, MCP-1, IP-10; anti-inflammatory cytokines 276 
TGF-β, IL-1RA, IFN-α; TH1-related cytokines IL-12, IL-15, IL-2R; and growth factors 277 
VEGF, FGF, HGF, IL-7 (Fig. 1). This variation was very pronounced for HGF, with a 278 
25 fold-change (Fig. 1). There was only one exception, eotaxin, whose concentration 279 
was significantly lower in placenta compared to peripheral plasma (Fig. 1).  280 
Biomarker concentrations were also higher in cord than peripheral plasma for the 281 
following markers: pro-inflammatory chemokines IL-8, MIP-1β, MCP-1; anti-282 
inflammatory cytokines TGF-β, IL-1RA, IFN-α; TH-related cytokines IL-12 and IL-17; 283 
and growth factors VEGF, HGF and GM-CSF (Fig. 2). The exceptions were IL-10 and 284 




Figure 1. Peripheral and placental plasma biomarker concentrations. Graphs depict biomarker concentrations in paired peripheral 287 
(Per) and placental (Pla) plasmas obtained at delivery. Concentrations for all biomarkers are expressed in pg/mL. N= 101, samples 288 
belong to women from Colombia or Papua New Guinea only. P-value corresponds to the Wilcoxon signed-rank test corrected for 289 




Figure 2. Peripheral and cord plasma biomarker concentrations. Graphs depict biomarker concentrations in paired peripheral (Per) 292 
and cord (Cord) plasmas obtained at delivery. Concentrations for all biomarkers are expressed in pg/mL. N= 61, samples belong to 293 
the five tropical study countries. P-value corresponds to the Wilcoxon signed-rank test corrected for multiple comparisons using the 294 
Benjamini-Hochberg test. *p<0.05, **p<0.01, ***p<0.001.  295 
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Figure 3. Biomarker concentrations at delivery by country. 299 
Graphs depict biomarker concentrations in peripheral plasma at delivery in individual countries. BCN: Barcelona control group, N=16; 300 
BR: Brazil, N=49; CO: Colombia, N=50; GT: Guatemala, N=50; IN: India, N=34; PNG: Papua New Guinea, N=50. P-value corresponds 301 
to a Kruskal-Wallis test followed by Dunn's multiple comparisons test of BCN versus each other country. *p<0.05, **p<0.01, 302 
***p<0.001.  303 
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3.4. Plasma biomarker concentrations at delivery vary between tropical 304 
countries and the control group 305 
Because the tropical cohort has been largely exposed to infectious diseases that have 306 
a chronic impact on the immune system, we analyzed differences on peripheral plasma 307 
biomarker concentrations measured at delivery between countries, including samples 308 
from BCN (controls). All biomarkers showed statistically significant differences 309 
between countries (Kruskal-Wallis test, p<0.05) except IL-10. When we compared 310 
biomarker concentrations between the control BCN group and each other country 311 
individually, we observed differences for most analytes, with women from tropical 312 
countries generally having higher levels than the control group. That was the case for 313 
the pro-inflammatory biomarkers TNF, IL-1β, IL-8, MIP-1α, MIP-1β, IP-10 and MIG, 314 
although the difference did not reach statistical significance for every country (Fig. 3A). 315 
Interestingly, the pro-inflammatory cytokine IL-6 showed lower concentrations in all 316 
countries compared to BCN (only statistically significant for BR, CO and GT), and 317 
RANTES concentrations were also lower in BR compared to BCN (Figure 3A). Other 318 
chemokines like MCP-1 or eotaxin did not show evident differences among countries 319 
(Fig. 3A). Regarding anti-inflammatory cytokines, women from BR and CO had 320 
consistently higher concentrations of TGF-β, IL1-RA and IFN-α than those from BCN 321 
(Fig. 3A). 322 
 The TH-related cytokines IFN-γ, IL-4 and IL-17 presented low plasma levels in 323 
general, with only few women having concentrations above the limit of detection, 324 
mostly from BR (Fig. 3A and 3B). In addition, TH1-related IL-12, IL-2, IL-2R and IL-15 325 
had increased plasma concentrations in women from tropical countries compared to 326 
BCN, although differences were not significant for every country. Furthermore, TH2-327 
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related IL-5 did not show statistically significant differences among countries and IL-13 328 
presented increased levels in women from BR and CO than BCN (Fig. 3B). 329 
 Additionally, women from tropical countries had increased concentrations of the 330 
growth factors EGF, FGF, HGF and VEGF compared to women from BCN, which was 331 
less evident in women from GT. Other growth factors such as G-CSF, GM-CSF and 332 
IL-7 showed overall lower concentrations in women from BCN, but only for Brazilian 333 
women the difference was significant (Fig. 3B). 334 
 We also performed a PCA with biomarkers measured at delivery. Six principal 335 
components (PC) resulted in a Eigenvalue>1 (overall kmo=0.8954); however two of 336 
them contributed mostly to variation, PC1 with 39% and PC2 with 11% (data not 337 
shown). Therefore only these two PC were further taken into account. When study 338 
subjects were displayed according to their predicted scores for PC1 and PC2, women 339 
from BCN grouped more homogenously (Fig 4A). Then, PCA analyses were performed 340 
separately for women from BCN and the tropical cohort, in order to detect if cytokines 341 
clustered differently in both groups. PC1 and PC2 eigenvectors for each biomarker 342 
were displayed, showing that while IL-6 and IL-8 clustered together in the tropical 343 













Figure 4. A principal component (PC) analysis of all biomarkers except TGF-β analyzed in 351 
peripheral plasmas collected at delivery from the tropical cohort (TROP, N=233) and Barcelona 352 
control cohort (BCN, N=16) was performed. A) Predicted PC1 and PC2 score values for each 353 
study subject are displayed. B) A loadingplot with PC1 and PC2 eigenvector values for each 354 
biomarker in the tropical and the control group is displayed. 355 
 356 
3.5. Plasma cytokine concentrations correlate with Plasmodium antibody levels 357 
at postpartum but not during pregnancy 358 
To test whether differences in biomarker concentrations between BCN and the five 359 
tropical countries were related to malaria exposure, we assessed the correlation 360 
between the biomarker concentrations and plasma levels of IgG against selected 361 
Plasmodium antigens measured at the same bleeding. Anti-Plasmodium IgG levels 362 
are frequently used as surrogate of malaria exposure. Correlations were analyzed 363 
separately at recruitment, delivery and postpartum.  364 
Overall, correlations at recruitment and delivery were weak or very weak. At 365 
recruitment, only anti-PvCSP-N antibodies presented a biologically relevant positive 366 
correlation with TGF-β, MIP-1β and HGF concentrations (Supplementary table 5). At 367 
delivery, anti-PvMSP5 IgG levels correlated negatively with TGF-β levels 368 
(Supplementary table 6).  369 
Postpartum, however, multiple potentially biologically relevant correlations were found 370 
(p<0.05 and Spearman's rho>0.4). TNF was the pro-inflammatory cytokine that 371 
showed better correlations, with moderate and strong negative associations for P. 372 
vivax as well as P. falciparum antibodies (Table 2). In contrast, IL-8 presented a 373 
relevant positive correlation with several antibodies. In the anti-inflammatory cytokine 374 
group, IFN-α levels correlated negatively with antibodies to merozoite antigens from 375 
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both species and anti-PfDBL6ε antibodies, while IL-10, TGF-β and IL-1RA did not show 376 
any biologically relevant correlations with antibody levels (Table 2).  377 
There were consistently negative moderate to strong correlations between several TH-378 
related cytokine concentrations (especially IFN-γ, IL-12, IL-4, IL-5, IL-13 and IL-17) 379 
and antibodies against both P. falciparum and P. vivax antigens (Table 2).  380 
Finally, the correlation pattern between antibodies and growth factors was very similar 381 
to the TH-related cytokines, with consistently negative moderate correlations between 382 
several (remarkably G-CSF, GM-CSF and IL-7) and antibodies against merozoite 383 
antigens of both species and PfDBL6ε (Table 2). 384 
  385 
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PvCSP-N 0,16 0,02 0,15 0,02 0,28 0,11 0,08 0,38 0,20 0,24 0,05 -0,05 -0,08 -0,23 0,09 0,18 -0,12 -0,06 -0,09 -0,07 0,12 0,11 0,20 0,15 0,28 -0,05 0,23 0,28 0,13 0,04 0,19 
PvCSP-C 0,07 0,09 0,14 -0,04 0,28 0,13 0,12 0,37 0,08 0,20 0,14 0,01 -0,10 -0,19 -0,04 0,06 -0,13 -0,07 -0,01 -0,01 0,04 0,07 0,12 0,06 0,20 -0,01 0,17 0,16 0,02 0,04 0,09 
PvCSP-R 0,03 0,18 0,18 -0,03 0,24 0,17 0,16 0,34 0,09 0,25 0,23 0,10 -0,06 -0,06 -0,14 0,05 -0,06 -0,02 0,03 0,01 -0,01 0,03 0,12 0,04 0,17 0,02 0,17 0,17 -0,01 0,05 0,10 
PvCSP -0,28 -0,05 -0,03 -0,09 -0,07 -0,12 -0,16 0,07 -0,16 -0,10 0,07 0,08 0,02 0,09 -0,11 -0,25 -0,18 -0,12 0,00 -0,13 -0,26 -0,25 -0,18 -0,25 -0,30 -0,18 -0,15 -0,16 -0,27 -0,12 -0,21 
PvDBP -0,48 0,05 -0,07 -0,22 -0,13 -0,28 -0,35 0,18 -0,27 -0,09 0,17 0,39 0,01 0,18 -0,14 -0,39 -0,32 -0,25 0,01 -0,32 -0,38 -0,37 -0,28 -0,40 -0,27 -0,17 -0,32 -0,20 -0,40 -0,35 -0,38 
PvMSP119 -0,46 0,09 0,03 -0,21 -0,18 -0,24 -0,31 0,17 -0,24 -0,08 0,17 0,28 -0,05 0,18 -0,16 -0,41 -0,33 -0,24 0,03 -0,26 -0,39 -0,35 -0,31 -0,38 -0,30 -0,14 -0,31 -0,16 -0,45 -0,34 -0,38 
Pv200L -0,37 0,00 -0,08 -0,24 -0,29 -0,31 -0,44 0,26 -0,21 -0,07 0,05 -0,03 -0,03 0,04 -0,05 -0,48 -0,53 -0,23 -0,14 -0,23 -0,41 -0,43 -0,42 -0,42 -0,35 -0,18 -0,34 -0,16 -0,45 -0,43 -0,47 
PvMSP1-N -0,28 -0,03 -0,08 -0,16 -0,07 -0,22 -0,30 0,27 -0,11 0,05 0,11 0,10 0,09 -0,02 -0,03 -0,28 -0,40 -0,15 -0,03 -0,15 -0,25 -0,25 -0,27 -0,21 -0,18 -0,07 -0,25 -0,13 -0,32 -0,22 -0,31 
PvMSP5 -0,42 0,04 -0,06 -0,26 -0,28 -0,30 -0,41 0,23 -0,20 -0,05 0,16 0,19 0,16 0,16 -0,05 -0,53 -0,47 -0,18 0,06 -0,24 -0,47 -0,47 -0,43 -0,44 -0,40 -0,19 -0,32 -0,22 -0,55 -0,43 -0,50 
VIR25 0,12 -0,09 0,04 -0,01 0,11 0,10 0,08 0,03 0,12 0,05 0,10 0,05 0,07 -0,10 0,15 0,05 0,02 0,02 0,06 0,11 0,05 0,02 -0,02 0,11 0,04 0,10 0,08 0,10 0,09 0,00 0,03 
VIR5 0,04 -0,08 0,04 -0,06 0,16 0,01 0,07 0,15 0,13 0,12 0,05 -0,19 0,09 -0,10 0,11 -0,02 -0,15 -0,03 -0,05 0,08 0,04 0,02 0,03 0,04 0,04 0,06 0,02 0,06 -0,01 -0,03 0,03 
LP1 -0,01 0,08 0,17 -0,07 0,24 0,07 -0,02 0,42 0,10 0,23 0,15 0,08 -0,16 -0,09 -0,05 0,03 -0,18 -0,14 -0,05 -0,05 0,00 -0,06 0,10 0,02 0,16 -0,06 0,11 0,16 0,01 -0,02 0,03 
LP2 -0,32 0,01 -0,08 -0,25 -0,04 -0,21 -0,32 0,41 -0,11 0,10 0,09 0,11 0,04 -0,06 -0,03 -0,31 -0,48 -0,25 -0,06 -0,28 -0,30 -0,37 -0,29 -0,28 -0,14 -0,15 -0,21 -0,03 -0,36 -0,40 -0,29 
PfMSP119 -0,45 -0,01 -0,09 -0,16 -0,35 -0,35 -0,50 0,30 -0,25 -0,05 0,10 0,10 0,03 0,07 -0,04 -0,53 -0,59 -0,22 -0,04 -0,31 -0,47 -0,47 -0,47 -0,48 -0,36 -0,26 -0,35 -0,19 -0,49 -0,40 -0,49 
PfAMA -0,50 -0,02 -0,09 -0,18 -0,31 -0,37 -0,58 0,36 -0,24 -0,03 0,10 0,12 0,05 0,08 0,01 -0,59 -0,65 -0,25 -0,01 -0,33 -0,52 -0,61 -0,52 -0,52 -0,42 -0,25 -0,40 -0,17 -0,56 -0,43 -0,53 
PfEBA175 -0,39 0,01 -0,11 -0,17 -0,30 -0,33 -0,55 0,27 -0,20 0,02 0,02 0,09 0,05 0,12 0,00 -0,54 -0,56 -0,27 -0,11 -0,36 -0,44 -0,60 -0,51 -0,43 -0,30 -0,22 -0,33 -0,15 -0,47 -0,39 -0,47 
PfDBL3x -0,15 0,07 0,06 -0,13 0,02 -0,06 -0,23 0,38 0,02 0,13 0,06 0,00 -0,09 -0,09 -0,05 -0,20 -0,41 -0,22 -0,16 -0,26 -0,18 -0,29 -0,17 -0,16 -0,02 -0,15 -0,01 0,09 -0,15 -0,16 -0,16 
PfDBL5ε -0,30 0,12 0,03 -0,14 0,02 -0,13 -0,29 0,35 -0,10 0,15 0,15 0,13 0,02 0,02 -0,11 -0,29 -0,31 -0,15 -0,02 -0,29 -0,30 -0,31 -0,15 -0,28 -0,09 -0,06 -0,11 0,11 -0,31 -0,22 -0,20 
PfDBL6ε -0,47 0,02 -0,08 -0,23 -0,15 -0,29 -0,42 0,24 -0,23 -0,01 0,08 0,01 -0,04 0,13 -0,19 -0,41 -0,45 -0,29 -0,14 -0,32 -0,41 -0,41 -0,30 -0,45 -0,30 -0,26 -0,31 -0,13 -0,45 -0,33 -0,40 
 Pro-inflammatory Anti-inflammatory Chemokines TH1 TH2 TH17 Growth factors 
Spearman's correlation coefficient (rho, range 0-|1|) is displayed in the cells. N=147. Grey-color scale (used for quick data comprehension) range from dark 387 
grey (Spearman's rho value=|0.65|) to white (Spearman's rho value=0). Bold indicates p<0.05 after multiple testing correction with the Benjamini-Hochberg 388 
method. Bold and squared indicates rho>0.4 AND p<0.05.389 
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4. Discussion 390 
Here we present a descriptive analysis of plasma cytokine, chemokine and growth 391 
factor concentrations during and after pregnancy in tropical areas. Although women 392 
were recruited in malaria-endemic countries, the prevalence of Plasmodium infection 393 
was very low, especially at delivery, thus the study cohort was malaria-exposed but 394 
not infected.  395 
Pregnant women were recruited at the first antenatal visit, regardless of gestational 396 
age. We could not perform a full longitudinal analysis of pregnancy (excluding delivery) 397 
but we were able to study the correlation of biomarker concentrations and gestational 398 
age, finding limited evidences of association, in contrast to a recent study showing in 399 
general higher biomarker levels in the second compared to the first trimester of 400 
pregnancy (8). Nevertheless, we observed that biomarker concentrations postpartum 401 
were higher than during pregnancy, and at delivery higher than at enrolment. The 402 
exceptions were the pro-inflammatory IL-1β and IL-6; the anti-inflammatory TGF-β; 403 
and IL-2, FGF and HGF, for which the highest concentrations were found at delivery, 404 
not at postpartum. Three of these biomarkers (IL-6, TGF-β and HGF) presented even 405 
higher concentrations in placental samples, suggesting an important role of these 406 
biomarkers in labor. Previous research in uncomplicated pregnancies had shown that 407 
IL-1, IL-6 and TNF (but not IL-10) were significantly up-regulated in sera of women in 408 
labor compared to women not in labor at term (10). Moreover, one recent study 409 
demonstrated that IL-8 and IL-6 produced during uncomplicated labor are actually of 410 
fetal origin, with the placenta having a prominent role in clearing them (especially IL-6) 411 
from fetal circulation (9). Thus, at present it is well accepted that parturition presents 412 
as a localized and physiological inflammatory process that favors the contraction of the 413 
uterus, the delivery of the baby and detachment of the placenta (29), explaining the 414 
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higher concentrations of proinflammatory cytokines observed at delivery. The TGF-β 415 
concentration and role have been assessed mainly in placenta/decidua at early 416 
pregnancy and in cord blood at delivery. Two studies showed higher levels of this anti-417 
inflammatory cytokine in cord blood after spontaneous vaginal delivery compared to 418 
elective caesarean section (with no labor) in term pregnancies (30,31). Thus, while in 419 
early pregnancy TGF-β is known to inhibit trophoblast invasion of uterine arteries (32), 420 
which may be associated with intrauterine growth retardation and preeclampsia, during 421 
labor TGF-β may counteract the excessive inflammation in the placenta/fetal interface 422 
(30,31). HGF has a role in cell proliferation, migration, and morphogenesis in different 423 
tissues and its elevated levels in placenta are well recognized (33).  424 
Our results show overall higher biomarker concentrations in both placenta (maternal 425 
side) and cord blood than in periphery. This suggests that either they are produced by 426 
the mother and traverse the placenta getting accumulated in the fetal circulation, or 427 
they are in fact produced by the fetus (9). However, a few exceptions were found in 428 
our study. First, MIG presented lower levels in cord and placenta. This chemokine is 429 
silenced in the murine decidua (34) and elevated MIG levels have been associated 430 
with poor outcomes in malaria-infected pregnant women (35,36) and in pregnant 431 
women with autoimmune thyroiditis (37). This might be the reason for presenting lower 432 
levels in the placenta and cord, compartments that are more related to the fetus. 433 
Second, eotaxin concentration was remarkably lower in placental than in peripheral 434 
plasma. The eotaxin receptor CCR3 is present in the placenta and the interaction with 435 
eotaxin-2/CCL24 in vitro favors decidualization (38) that is essential in early 436 
pregnancy. Thus, a reduced concentration of competitor eotaxin/CCL11 in the placenta 437 
seems logical in the context of uncomplicated pregnancies. Unfortunately, we could 438 
not measure eotaxin-2/CCL24 concentration in our samples, but microarray assays in 439 
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villous and extravillous trophoblast as well as decidual cells in early pregnancy have 440 
shown that mRNA expression of eotaxin-2 is at least two-times higher than expression 441 
of eotaxin (39). More studies about the role of eotaxin in pregnancy are necessary. 442 
Finally IL-10 was decreased in cord blood but not in placental plasma compared to 443 
periphery. This result contrasts partially with one recent publication showing that labor 444 
increases cord but decreases placental IL-10 concentrations compared to the same 445 
tissues after elective cesarean section with no labor (9). A study on IL-10 expression 446 
throughout pregnancy showed that just before and during labor placental IL-10 447 
expression is down-regulated (compared to early pregnancy) but PBMCs hold the 448 
capacity of secreting IL-10 (7), supporting our finding of increased IL-10 levels in 449 
periphery.  450 
The effect of pregnancy and labor on plasma biomarker concentrations in women from 451 
tropical countries followed a similar pattern to what has been described in the literature 452 
for uncomplicated pregnancies. However, when we specifically compared plasma 453 
biomarker concentrations at delivery between our cohort and the control group from 454 
BCN, women from all tropical countries showed consistently higher plasma 455 
concentrations of most biomarkers than pregnant women from BCN, with one clear 456 
exception: IL-6. This suggests a general over-activation of the women's immune 457 
system during labor in these countries, at least compared to the control group. 458 
Moreover, in the PCA analysis women from BCN seemed to group more 459 
homogenously than women from tropical countries, maybe as a result of this general 460 
activation of the immune system in the tropical cohort that is not equally presented in 461 
every woman.  462 
At postpartum, many biomarker concentrations correlated well with malaria antibody 463 
levels, suggesting that chronic malaria-exposure may have an impact on the circulating 464 
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cytokine profile, although it might just be a confounder of exposure to other pathogens 465 
or socio-demographic variables. However, at enrolment and delivery the correlation 466 
was poor or non-existent. The reason why pregnant women in tropical countries 467 
present a more activated status of the immune system at delivery, and whether this 468 
also happens throughout pregnancy, remain unclear, but these results should be taken 469 
into consideration when analyzing the immune impact of infections during pregnancy 470 
in tropical countries.  471 
As mentioned, despite general immune activation, women from tropical countries had 472 
lower IL-6 concentration than women from BCN, in contrast with all other biomarkers. 473 
Of note, in our PCA analysis at delivery, IL-6 clustered with IL-8 in the tropical cohort 474 
but segregated in an opposite PC2-direction in the control group. IL-6 is produced 475 
physiologically during labor (9) and can drive prostaglandin synthesis (40), inducing 476 
subsequently myometrial contractility. In early pregnancy, IL-6 may promote 477 
trophoblast invasion of spiral uterine arteries (at least in vitro) (41), a critical step for 478 
the establishment of maternal blood flow towards the placenta whose failure leads to 479 
miscarriage or pregnancy disorders such as intrauterine growth restriction (42). Thus, 480 
although elevated levels have been associated with negative outcomes during 481 
pregnancy including preterm delivery (43,44), gestational diabetes mellitus (45) or 482 
recurrent spontaneous abortion (46), IL-6 seems to also have a physiological and 483 
important role in pregnancy and parturition. Further studies are necessary to unravel if 484 
IL-6 “abnormal” levels at delivery in women from malaria-endemic areas have an 485 
impact on delivery outcomes. 486 
Our study presents some limitations. Some important clinical variables of the cohort 487 
were not recorded, such as smoking status or gestational diabetes. And although 488 
recorded, the blood pressure variable had multiple missing values. Moreover, other 489 
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infectious diseases were not analyzed except for syphilis screening. Finally, 490 
comparison of biomarker concentrations between uncomplicated pregnancies (from 491 
BCN) and pregnancies from tropical countries could only be done at delivery, as first 492 
trimester and postpartum samples were not collected in BCN. 493 
In summary, profiling of cytokine, chemokine and growth factor plasma concentrations 494 
during pregnancy in women from tropical countries showed a similar pattern to what 495 
has been described for uncomplicated pregnancies although with exacerbated or 496 
increased biomarker levels. The exception may be IL-6, an important pro-inflammatory 497 
cytokine during pregnancy and labor, which showed a decreased concentration in our 498 
cohort of women from tropical settings. 499 
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Figure legends 542 
 543 
Figure 1. Peripheral and placental plasma biomarker concentrations.  544 
Graphs depict biomarker concentration in paired peripheral (Per) and placental (Pla) 545 
plasmas obtained at delivery. Concentrations for all biomarkers are expressed in 546 
pg/mL. N= 101, samples belong to women from Colombia or Papua New Guinea only. 547 
P-value corresponds to the Wilcoxon signed-rank test. *p<0.05, **p<0.01, ***p<0.001.  548 
 549 
Figure 2. Peripheral and cord plasma biomarker concentrations.  550 
Graphs depict biomarker concentration in paired peripheral (Per) and cord (Cord) 551 
plasmas obtained at delivery. Concentrations for all biomarkers are expressed in 552 
pg/mL. N= 61, samples belong to the five tropical study countries. P-value corresponds 553 
to the Wilcoxon signed-rank test. *p<0.05, **p<0.01, ***p<0.001.  554 
 555 
Figure 3. Biomarker concentrations at delivery by country. 556 
Graphs depict biomarker concentration in peripheral plasma at delivery in individual 557 
countries. BCN: Barcelona control group, N=16; BR: Brazil, N=49; CO: Colombia, 558 
N=50; GT: Guatemala, N=50; IN: India, N=34; PNG: Papua New Guinea, N=50. P-559 
value corresponds to a Kruskal-Wallis test followed by Dunn's multiple comparisons 560 
test of BCN vs each other country. *p<0.05, **p<0.01, ***p<0.001.  561 
 562 
Figure 4. A principal component (PC) analysis of all biomarkers except TGF-β 563 
analyzed in peripheral plasmas collected at delivery from the tropical cohort (TROP, 564 
N=233) and Barcelona control cohort (BCN, N=16) was performed. A) Predicted PC1 565 
and PC2 score values for each study subject are displayed. B) A loadingplot with PC1 566 
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and PC2 eigenvector values for each biomarker in the tropical and the control group is 567 
displayed. 568 
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Table S1. Upper and lower values of the biomarker standard curves 
Biomarker Std 1 (upper) pg/mL Std 7 (lower) pg/mL 
TNF 8700 12 
IL1B 8300 11 
IL-6 4150 6 
IL-10 21900 30 
TGF-β 2500 39 
IL-1RA 28000 38 
IFN-α 12900 18 
IL-8 12800 18 
MIP-1α 25000 34 
MIP-1β 7200 10 
MCP1 6100 8 
IP10 900 1 
EOTAXIN 2900 4 
RANTES 3500 5 
MIG 2400 3 
IFN-γ 10500 14 
IL-12 6500 9 
IL-2 1200 1.6 
IL-15 24300 33 
IL-2R 21000 29 
IL-4 42600 58 
IL-5 2330 3 
IL-13 20300 28 
IL-17 38800 53 
EGF 12000 16 
FGF 2400 3 
HGF 7900 11 
VEGF 4400 6 
G-CSF 70000 96 
GM-CSF 17350 24 
IL-7 9800 13 
  
Table S2. Sample size by time point and country 
 


















Brazil 50 49 X 2 43 
Colombia 50 50 31 13 20 
Guatemala 50 50 X 21 50 
India 35 34 X X 11 
PNG 50 50 74 25 49 
 
Table S3. Baseline characteristics 
 
 BCN BR CO GT IN PNG p-value 
Age (years)a,b 30.4 (4.4) [16] 23.4 (5.7) [114] 22.0 (5.6) [114] 25.3 (7.9) [114] 23.3 (3.3) [66] 25.9 (6.0) [132] <0.0001c 
GA recruitment a N/R 23 (9) [111] 21 (9) [114] 27 (8) [112] 25 (7) [66] 24 (5) [138] <0.0001c 
Parityd 
0 6 (37) 31 ( 28) 34 (30) 41 (36) 30  (45) 56 (41) 
0.001e 1-3 7 (44) 59 (52) 56 (49) 34 (30) 32 (49) 51 (37) 
+4 3 (19) 23 (20) 24 (21) 39 (34) 4 (6) 30 (22) 
BMI a,b 26.0 (3.5) [16] 25.8 (4.4) [111] 23.3 (3.4) [113] 26.2 (3.7) [114] 22.9 (4.3) [66] 24.1 (3.5) [128] <0.0001
c 
GA deliverya 39.8 (1.0) [16] 39.1(1.6) [70] 37.9(2.3) [72] 39.6(2.1) [85] 36.4(1.5) [47] 37.8(3.5) [106] <0.0001
c 
Birth weigtha 3337 (490) [16] 3192 (494) [72] 3216 (406) [79] 3183 (527) [87] 2970 (452) [47] 2874 (512) [118] <0.0001
c 
Delivery mode 
V 12 (75) 59 (74) 64 (81) 62 (69) 40 (82) 119 (100) <0.0001f 
C 4 (25) 21 (26) 15( 19) 28 (31) 9 (18) 0 (0) 
Syphilis 
screening 
POS 0 (0) 0 (0) 6 (8) N/A 0 (0) 4 (5) 0.101f 
NEG 16 (100) 70 (100) 64 ( 92) N/A 16 (100) 81 (95) 
 
BCN: Barcelona (Spain); BR: Brazil; CO: Colombia; GT: Guatemala; IN: India; PNG: Papua New Guinea. GA: gestational age 
(weeks). BMI: body mass index (kg/m2). V: vaginal. C: cesarean section. POS: positive. NEG: negative. N/R: not relevant, samples 
available collected at delivery. N/A: not available. a Arithmetic Mean (standard deviation) [N]. b At recruitment. c One-way ANOVA. d 
N (percentage). e Chi-squared test.f Fisher's exact test.

























Rho: Spearman’s coefficient. q-value: p-value adjusted for multiple comparisons 
(Hochberg-Benjamini) 
 rho q-value 
TNF -0.044 0.860 
IL-1β 0.0122 0.860 
IL-6 0.0728 0.860 
IL-10 0.0485 0.860 
IL-1RA -0.2582 0.018 
TGF-β -0.1421 0.860 
IFN-α -0.0491 0.860 
IL-8 -0.0448 0.860 
MIP-1α -0.0873 0.860 
MIP-1β -0.162 0.500 
MCP-1 -0.0884 0.860 
IP-10 0.2179 0.042 
MIG 0.0263 0.860 
EOTAXIN -0.0826 0.860 
RANTES 0.0481 0.860 
IFN-γ -0.1217 0.860 
IL-12 -0.2171 0.042 
IL-2 -0.0241 0.860 
IL-15 0.1306 0.860 
IL-2R -0.0469 0.860 
IL-4 -0.0734 0.860 
IL-5 -0.0414 0.860 
IL-13 -0.0826 0.860 
IL-17 -0.1363 0.860 
EGF -0.3215 0.003 
FGF -0.0303 0.860 
HGF -0.1596 0.530 
VEGF -0.0129 0.860 
G-CSF -0.1109 0.860 
GM-CSF -0.069 0.860 
IL-7 -0.0592 0.860 











































































































PvCSP-N 0,11 0,12 0,20 0,16 0,40 0,28 0,26 0,27 0,25 0,41 0,03 -0,06 -0,13 -0,04 0,01 0,06 0,19 0,22 0,07 0,08 0,11 0,08 0,12 0,11 0,29 0,16 0,46 0,29 -0,05 0,08 0,12 
PvCSP-C 0,06 0,11 0,10 0,09 0,20 0,20 0,26 0,21 0,19 0,29 0,05 0,08 -0,05 -0,11 0,07 0,03 0,15 0,22 0,13 0,15 0,03 0,07 0,03 0,06 0,21 0,19 0,30 0,14 -0,01 0,01 0,08 
PvCSP-R 0,06 0,08 0,16 0,12 0,27 0,20 0,26 0,10 0,17 0,23 0,07 0,00 -0,07 -0,16 0,00 0,07 0,22 0,24 0,11 0,16 0,06 0,13 0,11 0,10 0,24 0,22 0,30 0,20 0,02 0,09 0,15 
PvCSP -0,10 -0,07 -0,04 -0,04 -0,31 -0,24 -0,15 0,01 -0,15 -0,17 -0,03 0,05 0,14 -0,06 0,00 -0,09 -0,26 -0,03 0,05 0,12 -0,02 -0,10 -0,25 -0,07 -0,28 -0,05 -0,31 -0,12 -0,13 -0,17 -0,19 
PvDBP -0,19 0,04 0,05 -0,02 -0,07 -0,02 0,00 0,18 -0,05 0,08 -0,11 0,05 -0,08 0,08 -0,01 -0,15 0,06 0,13 0,08 0,09 -0,10 -0,13 -0,19 -0,13 -0,04 -0,04 0,03 0,00 -0,32 -0,15 -0,11 
PvMSP119 -0,16 0,00 0,07 0,04 -0,17 -0,05 -0,01 0,14 -0,11 0,06 -0,08 0,07 0,05 0,17 0,03 -0,15 0,00 0,12 0,12 0,18 -0,08 -0,15 -0,23 -0,13 -0,12 -0,01 -0,07 0,07 -0,32 -0,11 -0,16 
Pv200L -0,13 0,07 0,10 0,09 -0,21 -0,06 0,00 0,20 -0,04 0,09 -0,02 0,06 0,07 0,05 0,06 -0,17 -0,07 0,07 0,10 0,08 -0,05 -0,19 -0,23 -0,07 -0,14 -0,01 -0,05 0,08 -0,26 -0,12 -0,21 
PvMSP1-N -0,04 0,03 -0,05 0,10 -0,27 -0,06 0,03 0,09 -0,01 0,07 -0,01 0,09 0,14 0,12 0,11 -0,02 -0,13 0,07 0,11 0,10 -0,06 -0,07 -0,11 0,02 -0,18 -0,03 -0,19 -0,03 -0,20 -0,05 -0,15 
PvMSP5 -0,08 0,04 -0,04 -0,09 -0,37 -0,13 -0,09 0,07 -0,12 -0,03 0,01 0,06 0,20 0,12 0,08 -0,20 -0,16 0,01 0,09 0,09 -0,16 -0,17 -0,26 -0,15 -0,29 -0,09 -0,25 -0,06 -0,26 -0,19 -0,24 
VIR25 0,12 -0,14 0,04 0,09 0,04 -0,05 0,08 -0,05 -0,02 0,02 0,02 -0,07 0,09 -0,08 -0,01 0,17 0,02 -0,02 -0,07 0,03 0,11 0,16 0,06 0,15 0,02 -0,01 -0,01 0,05 0,02 0,07 0,05 
VIR5 0,01 -0,05 -0,01 0,01 -0,18 -0,10 -0,06 0,01 0,02 0,03 -0,02 -0,02 0,12 -0,03 0,04 0,10 -0,17 -0,01 -0,01 -0,01 0,04 0,07 -0,06 0,05 -0,17 -0,02 -0,14 -0,07 0,00 0,00 -0,08 
LP1 0,06 0,12 0,14 0,12 0,22 0,17 0,20 0,24 0,14 0,27 0,02 0,07 0,00 -0,04 0,08 0,05 0,13 0,17 0,11 0,19 0,08 0,06 0,05 0,11 0,19 0,15 0,28 0,21 -0,06 0,05 0,09 
LP2 -0,13 0,02 0,05 -0,01 0,02 0,03 0,06 0,28 0,00 0,21 -0,08 0,01 -0,02 0,03 0,01 -0,10 -0,02 0,12 0,09 0,06 -0,03 -0,10 -0,10 -0,06 0,03 -0,02 0,10 0,08 -0,28 -0,15 -0,12 
PfMSP119 -0,15 0,03 0,05 -0,01 -0,26 -0,05 -0,05 0,19 -0,06 0,11 -0,08 0,11 0,07 0,17 0,09 -0,19 -0,04 0,07 0,14 0,19 -0,07 -0,16 -0,25 -0,09 -0,14 -0,07 -0,06 0,00 -0,28 -0,23 -0,23 
PfAMA -0,15 -0,05 0,03 -0,01 -0,29 -0,12 -0,12 0,20 -0,11 0,03 -0,11 0,10 0,08 0,19 0,11 -0,16 -0,08 -0,03 0,04 0,10 -0,06 -0,22 -0,31 -0,09 -0,23 -0,16 -0,11 -0,03 -0,27 -0,21 -0,30 
PfEBA175 -0,14 -0,04 0,00 -0,02 -0,19 -0,07 -0,09 0,21 -0,11 0,10 -0,14 0,08 0,01 0,19 0,04 -0,11 -0,07 -0,05 0,01 0,09 -0,08 -0,17 -0,25 -0,03 -0,12 -0,16 -0,04 0,02 -0,23 -0,18 -0,21 
PfDBL3x -0,06 0,01 0,09 0,04 0,17 0,09 0,11 0,23 0,07 0,23 -0,08 -0,09 -0,09 -0,06 0,00 -0,02 0,06 0,10 -0,03 0,07 0,02 -0,04 -0,06 0,01 0,09 0,00 0,24 0,11 -0,15 -0,07 -0,01 
PfDBL5ε -0,17 0,01 0,08 -0,02 0,04 0,00 0,04 0,21 -0,04 0,12 -0,11 -0,03 -0,02 0,06 -0,01 -0,10 0,02 0,10 0,02 0,10 -0,04 -0,09 -0,11 -0,08 -0,02 0,00 0,13 0,09 -0,23 -0,16 -0,07 
PfDBL6ε -0,13 -0,02 0,07 0,00 -0,03 -0,01 -0,04 0,19 0,02 0,12 -0,07 0,00 -0,05 0,06 -0,05 -0,12 0,02 0,06 0,03 0,11 0,00 -0,07 -0,13 -0,08 -0,03 -0,04 0,03 0,05 -0,19 -0,18 -0,09 
 
Spearman's correlation coefficient (rho, range 0-1) is shown (N=213) in a grey-color scale ranging from dark grey (Spearman's rho value=0.65) 
to white (Spearman's rho value=0). Bold numbers indicate p<0.05 after multiple correction adjustment by the Benjamin-Hochberg method; bold 
numbers and margins on a cell indicate rho>0.4 AND p<0.05. 
 
 











































































































PvCSP-N 0,05 0,09 0,07 0,15 0,24 0,14 0,12 0,02 0,11 0,15 0,08 0,01 -0,07 0,01 0,11 0,00 -0,02 0,12 0,00 0,09 0,02 -0,04 0,23 0,01 0,16 0,09 0,30 0,23 -0,02 0,10 0,05 
PvCSP-C 0,03 0,16 0,07 0,11 0,07 0,14 0,09 0,02 0,10 0,12 0,05 -0,01 -0,03 0,15 0,18 0,03 0,08 0,19 0,06 0,13 -0,02 0,06 0,19 0,02 0,10 0,17 0,24 0,18 -0,03 0,09 0,10 
PvCSP-R 0,00 0,13 0,00 0,05 0,11 0,14 0,11 0,06 0,05 0,09 0,02 -0,07 -0,14 0,14 0,06 -0,05 0,10 0,17 0,00 0,14 -0,07 0,01 0,16 -0,03 0,08 0,14 0,23 0,13 -0,05 0,05 0,06 
PvCSP -0,17 -0,11 -0,01 0,01 -0,21 -0,17 -0,16 -0,09 -0,12 -0,10 -0,06 0,03 -0,05 0,05 -0,09 -0,13 -0,33 -0,07 0,03 -0,05 -0,04 -0,19 -0,25 -0,17 -0,12 -0,11 -0,20 -0,09 -0,18 -0,13 -0,27 
PvDBP -0,01 0,09 0,01 0,03 -0,12 0,08 0,09 -0,07 0,00 0,01 -0,01 0,00 0,03 0,05 0,18 -0,03 0,03 0,10 0,11 0,23 0,04 0,00 0,09 0,10 -0,05 0,06 0,13 0,09 0,04 0,04 -0,01 
PvMSP119 -0,05 0,06 0,00 0,09 -0,18 0,01 0,00 -0,13 -0,06 -0,07 -0,07 0,05 -0,04 0,16 0,16 -0,07 -0,07 0,04 0,12 0,24 0,02 -0,01 -0,03 0,06 -0,12 0,02 -0,02 -0,01 -0,06 -0,01 -0,13 
Pv200L -0,12 0,02 0,10 0,04 -0,34 -0,06 -0,04 -0,08 -0,06 -0,07 -0,05 -0,10 -0,04 0,18 0,09 -0,22 -0,16 -0,04 0,00 0,16 -0,09 -0,12 -0,10 -0,03 -0,21 -0,01 -0,05 0,01 -0,08 -0,03 -0,19 
PvMSP1-N -0,03 -0,01 -0,07 0,10 -0,32 -0,10 -0,03 -0,17 -0,03 -0,07 -0,04 0,00 0,06 0,09 0,09 -0,08 -0,19 -0,03 0,07 0,07 0,03 -0,08 -0,17 0,05 -0,12 -0,03 -0,14 -0,05 -0,14 -0,03 -0,11 
PvMSP5 -0,05 -0,04 0,08 0,07 -0,42 -0,09 -0,07 -0,14 -0,05 -0,10 0,01 0,02 0,05 0,05 0,11 -0,18 -0,23 -0,08 0,12 0,13 -0,05 -0,07 -0,20 -0,06 -0,28 -0,08 -0,15 -0,06 -0,11 -0,10 -0,25 
VIR25 -0,13 -0,14 -0,11 -0,08 0,11 -0,15 -0,01 -0,11 -0,10 -0,09 -0,02 0,00 0,01 -0,03 0,04 -0,06 -0,15 -0,01 -0,02 -0,10 0,04 -0,04 -0,05 -0,09 -0,02 -0,11 -0,14 -0,06 -0,17 -0,13 -0,07 
VIR5 -0,11 -0,10 0,00 0,05 -0,23 -0,19 -0,15 -0,09 -0,08 -0,05 -0,07 -0,03 0,01 0,14 0,05 -0,13 -0,21 -0,03 -0,04 -0,11 -0,09 -0,05 -0,08 -0,13 -0,20 -0,07 -0,20 -0,06 -0,13 -0,07 -0,07 
LP1 0,08 0,13 -0,01 0,07 0,01 0,12 0,11 -0,05 0,06 0,11 0,03 -0,04 -0,03 0,09 0,16 -0,01 0,03 0,15 0,06 0,17 0,03 0,02 0,17 0,07 0,05 0,10 0,20 0,16 -0,01 0,08 0,05 
LP2 -0,06 0,07 0,07 0,04 -0,04 0,06 0,03 0,01 0,02 0,06 0,02 -0,07 0,03 0,13 0,17 -0,03 -0,08 0,09 0,05 0,14 -0,01 -0,05 0,12 0,02 -0,04 0,06 0,17 0,14 -0,03 -0,02 0,02 
PfMSP119 -0,13 -0,11 0,00 -0,04 -0,34 -0,12 -0,13 -0,11 -0,15 -0,11 -0,14 -0,14 -0,11 0,22 0,06 -0,14 -0,24 -0,09 -0,04 0,13 -0,03 -0,11 -0,08 -0,11 -0,26 -0,13 -0,13 -0,13 -0,14 -0,07 -0,16 
PfAMA -0,14 -0,09 0,04 0,01 -0,28 -0,17 -0,16 -0,08 -0,10 -0,12 -0,10 -0,12 0,03 0,14 0,12 -0,11 -0,29 -0,10 0,00 0,11 -0,05 -0,14 -0,13 -0,07 -0,25 -0,15 -0,12 -0,09 -0,15 -0,08 -0,19 
PfEBA175 -0,11 -0,06 0,11 -0,02 -0,18 -0,16 -0,16 -0,03 -0,09 -0,08 -0,11 -0,02 -0,11 0,14 0,04 -0,14 -0,27 -0,07 -0,04 0,02 -0,10 -0,21 -0,08 -0,11 -0,21 -0,07 -0,08 0,01 -0,11 -0,09 -0,19 
PfDBL3x -0,02 0,07 0,09 -0,01 0,10 0,04 0,01 0,02 -0,01 0,05 0,02 -0,05 -0,04 0,00 0,12 -0,05 -0,12 0,06 -0,05 0,00 -0,05 -0,11 0,11 -0,05 0,03 0,05 0,18 0,11 -0,08 -0,06 -0,02 
PfDBL5ε -0,13 0,01 -0,02 0,00 -0,04 0,01 -0,03 -0,01 -0,02 0,04 -0,02 -0,05 -0,02 0,12 0,07 -0,18 -0,16 0,00 -0,02 0,08 -0,11 -0,10 0,06 -0,11 -0,04 0,00 0,08 0,05 -0,13 -0,07 -0,06 
PfDBL6ε -0,14 -0,01 0,12 -0,03 -0,13 -0,09 -0,13 0,03 -0,08 -0,01 -0,12 0,07 -0,06 0,18 0,04 -0,19 -0,17 -0,09 0,04 0,07 -0,11 -0,10 -0,04 -0,13 -0,14 -0,02 -0,04 0,04 -0,11 -0,09 -0,14 
 
Spearman's correlation coefficient (rho, range 0-1) is shown (N=213) in a grey-color scale ranging from dark grey (Spearman's rho value=0.65) 
to white (Spearman's rho value=0). Bold numbers indicate p<0.05 after multiple correction adjustment by the Benjamin-Hochberg method; bold 
numbers and margins on a cell indicate rho>0.4 AND p<0.05. 
 
